Exact Sciences Corp Reports Robust Revenue Growth and Positive Free Cash Flow in Q4 2023
Exact Sciences Corp (EXAS) Announces 17% Revenue Increase and Provides Optimistic 2024 Outlook
Stay updated with breaking news from Exact Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exact Sciences Corp (EXAS) Announces 17% Revenue Increase and Provides Optimistic 2024 Outlook
MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Wednesday reported a loss of $49.8 million in its fourth quarter.
The rise of GLP-1 weight-loss drugs has arguably been the second-hottest trend in the stock market right now — second to generative artificial intelligence (AI). Undoubtedly, the “GLP-1 run” has brought a great deal of enthusiasm to the biotechnology and healthcare scenes. However, I don’t expect it’ll be the last ground-breaking innovation from the health space over the coming years. As AI and biotech join forces, there’s no telling where the healthcare scene could be headed next. In any case,
That’s the theory behind the March 18 Wisconsin Tech Summit at Green Bay’s Lambeau Field.
Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) CFO Jeffrey Thomas Elliott sold 1,888 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total value of $115,979.84. Following the completion of the transaction, the chief financial officer now […]